The anaplastic lymphoma kinase in the pathogenesis of cancer

被引：704

作者：

Chiarle, Roberto ^{[1
,2
]}

Voena, Claudia ^{[1
,2
]}

Ambrogio, Chiara ^{[1
,2
]}

Piva, Roberto ^{[1
,2
,3
,4
]}

Inghirami, Giorgio ^{[1
,2
,3
,4
]}

机构：

[1] Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy

[2] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy

[3] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA

[4] NYU, Sch Med, New York Canc Ctr, New York, NY 10016 USA

来源：

NATURE REVIEWS CANCER | 2008年 / 8卷 / 01期

关键词：

D O I：

10.1038/nrc2291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas. The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many molecular mechanisms. In this Review, we will analyse how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacological tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.

引用

收藏

页码：11 / 23

页数：13

相关论文

共 159 条

[1]

A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation [J].

Adam, P ;

Katzenberger, T ;

Seeberger, H ;

Gattenlöhner, S ;

Wolf, J ;

Steinlein, C ;

Schmid, M ;

Müller-Hermelink, HK ;

Ott, G .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (11) :1473-1476

[2]

B and CTL responses to the ALK protein in patients with ALK-positive ALCL [J].

Ait-Taharl, K ;

Cerundolo, V ;

Banham, AH ;

Hatton, C ;

Blanchard, T ;

Kusec, R ;

Becker, M ;

Smith, GL ;

Pulford, K .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (03) :688-695

[3]

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase [J].

Ambrogio, C ;

Voena, C ;

Manazza, AD ;

Piva, R ;

Riera, L ;

Barberis, L ;

Costa, C ;

Tarone, G ;

Defilippi, P ;

Hirsch, E ;

Erba, EB ;

Mohammed, S ;

Jensen, ON ;

Palestro, G ;

Inghirami, G ;

Chiarle, R .

BLOOD, 2005, 106 (12) :3907-3916

[4]

Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma [J].

Amin, HM ;

Medeiros, LJ ;

Ma, Y ;

Feretzaki, M ;

Das, P ;

Leventaki, V ;

Rassidakis, GZ ;

O'Connor, SL ;

McDonnell, TJ ;

Lai, R .

ONCOGENE, 2003, 22 (35) :5399-5407

[5]

Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells [J].

Armstrong, F ;

Duplantier, MM ;

Trempat, P ;

Hieblot, C ;

Lamant, L ;

Espinos, E ;

Racaud-Sultan, C ;

Allouche, M ;

Campo, E ;

Delsol, G ;

Touriol, C .

ONCOGENE, 2004, 23 (36) :6071-6082

[6]

TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins [J].

Armstrong, Florence ;

Lamant, Laurence ;

Hieblot, Corinne ;

Delsol, Georges ;

Touriol, Christian .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) :640-646

[7]

Activation of α-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase [J].

Bacchiocchi, R ;

Baldanzi, G ;

Carbonari, D ;

Capomagi, C ;

Colombo, E ;

van Blitterswijk, WJ ;

Graziani, A ;

Fazioli, F .

BLOOD, 2005, 106 (06) :2175-2182

[8]

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity [J].

Bai, RY ;

Dieter, P ;

Peschel, C ;

Morris, SW ;

Duyster, J .

MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (12) :6951-6961

[9]

Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway [J].

Bai, RY ;

Tao, OY ;

Miething, C ;

Morris, SW ;

Peschel, C ;

Duyster, J .

BLOOD, 2000, 96 (13) :4319-4327

[10]

Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia [J].

Basecke, J ;

Cepek, L ;

Mannhalter, C ;

Krauter, J ;

Hildenhagen, S ;

Brittinger, G ;

Trumper, L ;

Griesinger, F .

BLOOD, 2002, 100 (06) :2267-2268

← 1 2 3 4 5 6 7 8 9 10 →